What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge – Image for illustrative purposes only (Image credits: Pexels)
Medicare and Medicaid programs have long faced limits on covering GLP-1 medications for weight management, leaving many beneficiaries without reliable options despite the drugs’ growing role in treating obesity and related conditions. The Centers for Medicare & Medicaid Services has now introduced structured demonstration efforts to address those gaps through negotiated pricing and temporary bridges to broader coverage. These steps reflect a deliberate effort to balance expanded access with cost controls for public insurance programs that serve tens of millions of Americans.
Current Coverage Limits and the Push for Change
GLP-1 receptor agonists such as semaglutide and tirzepatide have transformed treatment for type 2 diabetes and, more recently, obesity. Yet Medicare Part D plans have historically covered these drugs only for approved indications like diabetes or certain cardiovascular risks, while Medicaid coverage has varied widely by state. This patchwork approach has created uneven access and high out-of-pocket costs for many enrollees who could benefit from the medications alongside lifestyle changes.
CMS recognized that sustained use often requires both pharmaceutical support and structured nutrition and activity programs. The agency therefore developed voluntary models that combine lower negotiated prices with requirements for evidence-based lifestyle interventions, aiming to improve long-term health outcomes without shifting unsustainable expenses to taxpayers or plans.
How the BALANCE Model Works
The BALANCE Model, short for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth, allows CMS to negotiate directly with manufacturers on behalf of participating state Medicaid agencies and Medicare Part D plans. Under the framework, selected GLP-1 products become available at reduced net prices, with standardized clinical criteria for eligibility and commitments from manufacturers to supply lifestyle support services such as coaching and counseling.
State Medicaid programs can begin joining on a rolling basis starting in May 2026, with the model running through December 2031. For Medicare Part D, the original target launch was January 2027, though some reports indicate potential adjustments based on plan participation levels. The approach remains voluntary for plans and states, giving them flexibility while providing CMS with data on utilization and outcomes.
Beneficiaries must meet specific clinical thresholds, often tied to body mass index and comorbidities, and receive prescriptions from providers who attest to ongoing lifestyle efforts. This structure seeks to ensure the medications are used as part of comprehensive care rather than in isolation.
The Medicare GLP-1 Bridge as an Interim Step
To provide earlier relief while the full BALANCE Model takes shape for Medicare, CMS created the Medicare GLP-1 Bridge demonstration. Beginning July 1, 2026, and now extended through December 31, 2027, eligible Part D beneficiaries can access certain GLP-1 medications at a flat $50 monthly copayment.
The Bridge operates outside standard Part D payment flows, with CMS handling centralized claims processing and reimbursing pharmacies at negotiated rates. This separation shields plan sponsors from immediate financial risk and allows collection of real-world data to inform future implementation. Manufacturers have agreed to supply the drugs at a net price around $245 per month under the demonstration.
Eligibility follows similar clinical criteria to the broader model, including age and BMI thresholds plus qualifying conditions such as heart failure, hypertension, or chronic kidney disease. The program applies nationwide to beneficiaries in standalone Part D plans or Medicare Advantage plans with drug coverage.
Stakeholders and Expected Effects
Beneficiaries stand to gain the most immediate practical benefit through lower and more predictable costs, potentially improving adherence for those who meet the criteria. State Medicaid agencies gain a tool to expand coverage without bearing full negotiation burdens, while Part D plans receive advance data from the Bridge period to prepare for possible wider participation.
Program budgets face new pressures from increased utilization, yet the negotiated pricing and lifestyle components are designed to generate offsetting savings through reduced complications from obesity-related diseases. Manufacturers participate voluntarily but commit to both price concessions and support services.
Overall, the combined initiatives represent a measured expansion rather than an open-ended entitlement, with built-in evaluation periods to assess sustainability.
What matters now: Eligible Medicare beneficiaries can prepare for Bridge access starting this July, while states and plans should review application timelines for BALANCE participation to shape coverage in the years ahead.
The coming months will reveal how many states and plans opt in and how quickly beneficiaries begin using the new pathways. Success will ultimately depend on whether the combination of affordable medications and lifestyle support delivers measurable improvements in health without exceeding projected costs.
